Professional Media briefs: August 2012

Professional Media briefs: August 2012
Professional Media briefs: August 2012

Quadrant Health has created two new leadership positions: Margo Ullman is now the Vice President/Digital Custom Solutions for QHI. She was previously the Group Publisher for the Women's Health Alliance. John Baranowski was appointed Vice President/Editorial Director of QUI. He was previously editor of OBG Management.

Springer Science + Business Media has increased its visibility. The publisher said that 10% of the company's open-access journals have an impact factor, which is measured by the Thomson Reuters Journal Citation Reports. The report also said that 62 Springer journals landed their very first impact factor last year; 19 of them were open-access titles.

The American ­Journal of Preventive Medicine is going off the page to find ways to treat childhood obesity. The publication, in tandem with the Robert Wood Johnson Foundation, has launched the Childhood Obesity Challenge to solicit effective strategies to combat the problem. An eight-person panel will judge entries based on innovativeness, real-world efficacy and the potential impact. The prizes include $2,500 to the winning team or individual and $2,500 in other prizes.
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.